Shares of Hologic, Inc. (NASDAQ:HOLX) have received an average recommendation of “Buy” from the fifteen analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $48.55.
Several equities research analysts recently weighed in on the stock. Royal Bank Of Canada reiterated a “sector perform” rating and set a $45.00 price objective (down previously from $50.00) on shares of Hologic in a research note on Wednesday, August 9th. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Jefferies Group LLC set a $49.00 price objective on shares of Hologic and gave the stock a “buy” rating in a research note on Sunday, May 28th. Barclays PLC reiterated an “equal weight” rating and set a $51.00 price objective (down previously from $53.00) on shares of Hologic in a research note on Wednesday, August 9th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hologic in a research note on Tuesday, August 1st.
In other news, Director Elaine Ullian sold 8,849 shares of the stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $45.28, for a total value of $400,682.72. Following the completion of the transaction, the director now directly owns 23,810 shares in the company, valued at $1,078,116.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Karleen Marie Oberton sold 4,704 shares of the stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $45.19, for a total transaction of $212,573.76. The disclosure for this sale can be found here. Insiders sold 27,594 shares of company stock worth $1,168,871 in the last 90 days. 0.79% of the stock is owned by company insiders.
Institutional investors have recently bought and sold shares of the company. Hall Laurie J Trustee boosted its holdings in shares of Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares in the last quarter. Commonwealth Bank of Australia boosted its holdings in shares of Hologic by 31.0% in the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares in the last quarter. TrimTabs Asset Management LLC boosted its holdings in shares of Hologic by 88.8% in the first quarter. TrimTabs Asset Management LLC now owns 2,993 shares of the medical equipment provider’s stock valued at $127,000 after acquiring an additional 1,408 shares in the last quarter. National Asset Management Inc. bought a new position in shares of Hologic in the second quarter valued at approximately $203,000. Finally, Miles Capital Inc. bought a new position in shares of Hologic in the first quarter valued at approximately $206,000. Institutional investors and hedge funds own 96.39% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Brokerages Set Hologic, Inc. (HOLX) PT at $48.55” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://transcriptdaily.com/2017/09/17/brokerages-set-hologic-inc-holx-pt-at-48-55.html.
Hologic (NASDAQ HOLX) traded down 0.05% during trading on Wednesday, hitting $37.72. The company had a trading volume of 3,344,455 shares. The company’s 50 day moving average price is $38.90 and its 200-day moving average price is $42.58. The company has a market cap of $10.58 billion, a PE ratio of 14.05 and a beta of 0.92. Hologic has a 12 month low of $35.15 and a 12 month high of $46.80.
Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.01. The firm had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. Hologic’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.51 earnings per share. Equities analysts expect that Hologic will post $2.01 earnings per share for the current year.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.